Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer

被引:10
|
作者
Kramer, Gerbrand M. [1 ]
Yaqub, Maqsood [1 ]
Vargas, Herbert A. [2 ]
Schuit, Robert C. [1 ]
Windhorst, Albert D. [1 ]
van den Eertwegh, Alfonsus J. M. [3 ]
van der Veldt, Astrid A. M. [4 ,5 ,6 ,7 ]
Bergman, Andries M. [4 ]
Burnazi, Eva M. [2 ]
Lewis, Jason S. [2 ,8 ]
Chua, Sua [9 ]
Staton, Kevin D. [2 ]
Beattie, Brad J. [10 ]
Humm, John L. [10 ]
Davis, Ian D. [11 ,12 ]
Weickhardt, Andrew J. [13 ]
Scott, Andrew M. [13 ,14 ]
Morris, Michael J. [15 ,16 ]
Hoekstra, Otto S. [1 ]
Lammertsma, Adriaan A. [1 ]
机构
[1] Vrije Univ Amsterdam, Amsterdam UMC, Dept Radiol & Nucl Med, POB 7057, NL-1007 MB Amsterdam, Netherlands
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA
[3] Vrije Univ Amsterdam, Amsterdam UMC, Dept Med Oncol, Amsterdam, Netherlands
[4] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[5] Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands
[6] Erasmus MC, Dept Radiol, Rotterdam, Netherlands
[7] Erasmus MC, Dept Nucl Med, Rotterdam, Netherlands
[8] Weill Cornell Med, Dept Radiol, New York, NY USA
[9] Royal Marsden NHS Fdn Trust, Dept Nucl Med, Sutton, Surrey, England
[10] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA
[11] Monash Univ, Box Hill, Vic, Australia
[12] Eastern Hlth, Eastern Hlth Clin Sch, Box Hill, Vic, Australia
[13] Austin Hosp, Olivia Newton John Canc Res Inst, Dept Med Oncol, Melbourne, Vic, Australia
[14] Univ Melbourne, Dept Mol Imaging & Therapy, Heidelberg, Vic, Australia
[15] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[16] Weill Cornell Med, Dept Med, New York, NY USA
基金
英国医学研究理事会;
关键词
FDHT; PET/CT; prostate cancer; quantification; PET/CT; 16-BETA-F-18-FLUORO-5-ALPHA-DIHYDROTESTOSTERONE; REPEATABILITY; ENZALUTAMIDE;
D O I
10.2967/jnumed.118.220111
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
F-18-fluorodihydrotestosterone (F-18-FDHT) PET/CT potentially provides a noninvasive method for assessment of androgen receptor expression in patients with metastatic castration-resistant prostate cancer (mCRPC). The objective of this study was to assess simplified methods for quantifying F-18-FDHT uptake in mCRPC patients and to assess effects of tumor perfusion on these F-18-FDHT uptake metrics. Methods: Seventeen mCRPC patients were included in this prospective observational multicenter study. Test and retest 30-min dynamic F-18-FDHT PET/CT scans with venous blood sampling were performed in 14 patients. In addition, arterial blood sampling and dynamic O-15-H2O scans were obtained in a subset of 6 patients. Several simplified methods were assessed: Patlak plots; SUV normalized to body weight (SUVBW), lean body mass (SUVLBM), whole blood (SUVWB), parent plasma activity concentration (SUVPP), area under the parent plasma curve (SUVAUC,PP), and area under the whole-blood input curve (SUVAUC,WB); and SUVBW corrected for sex hormone-binding globulin levels (SUVSHBG). Results were correlated with parameters derived from full pharmacokinetic F-18-FDHT and O-15-H2O. Finally, the repeatability of individual quantitative uptake metrics was assessed. Results: Eighty-seven F-18-FDHT-avid lesions were evaluated. F-18-FDHT uptake was best described by an irreversible 2-tissue-compartment model. Replacing the continuous metabolite-corrected arterial plasma input function with an image-derived input function in combination with venous sample data provided similar K-i results (R-2 = 0.98). Patlak K-i and SUVAUC,PP showed an excellent correlation (R-2 > 0.9). SUVBW showed a moderate correlation to K-i (R-2 = 0.70, presumably due to fast F-18-FDHT metabolism. When calculating SUVSHBG, correlation to K-i improved (R-2 = 0.88). The repeatability of full kinetic modeling parameters was inferior to that of simplified methods (repeatability coefficients. 36% vs., 28%, respectively). F-18-FDHT uptake showed minimal blood flow dependency. Conclusion: F-18-FDHT kinetics in mCRPC patients are best described by an irreversible 2-tissue-compartment model with blood volume parameter. SUVAUC, PP showed a near-perfect correlation with the irreversible 2-tissue-compartment model analysis and can be used for accurate quantification of F-18-FDHT uptake in whole-body PET/CT scans. In addition, SUVSHBG could potentially be used as an even simpler method to quantify F-18-FDHT uptake when less complex scanning protocols and accuracy are required.
引用
收藏
页码:1221 / 1227
页数:7
相关论文
共 50 条
  • [41] Adverse events and costs among non-metastatic castration-resistant prostate cancer patients
    Appukkuttan, Sreevalsa
    Yao, Jianying
    Partridge, Jamie
    Kong, Sheldon X.
    Parkin, Jacqueline
    Freedland, Stephen J.
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 145 - 152
  • [42] Prevalence of mutations in DNA repair genes in Russian patients with metastatic castration-resistant prostate cancer
    Mailyan, O. A.
    Kalpinskiy, A. S.
    Reshetov, I., V
    Anzhiganova, Yu, V
    Nyushko, K. M.
    Golovashchenko, M. P.
    Kokin, S. P.
    Stakanov, V. A.
    Alekseev, B. Ya
    ONKOUROLOGIYA, 2022, 18 (03): : 60 - 66
  • [43] Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
    Di Lorenzo, Giuseppe
    Sonpavde, Guru
    Pond, Gregory
    Lucarelli, Giuseppe
    Rossetti, Sabrina
    Facchini, Gaetano
    Scagliarini, Sarah
    Carteni, Giacomo
    Federico, Piera
    Daniele, Bruno
    Morelli, Franco
    Bellelli, Teresa
    Ferro, Matteo
    De Placido, Sabino
    Buonerba, Carlo
    EUROPEAN UROLOGY FOCUS, 2018, 4 (06): : 874 - 879
  • [44] Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer
    Oudard, Stephane
    Kramer, Gero
    Caffo, Orazio
    Creppy, Lorraine
    Lorio, Yohan
    Hansen, Steinbjoern
    Holmberg, Mats
    Rolland, Frederic
    Machiels, Jean-Pascal
    Krainer, Michael
    BJU INTERNATIONAL, 2015, 115 (05) : 744 - 752
  • [45] Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients
    ten Ham, Renske M. T.
    van Nuland, Merel
    Vreman, Rick A.
    de Graaf, Laurens G.
    Rosing, Hilde
    Bergman, Andre M.
    Huitema, Alwin D. R.
    Beijnen, Jos H.
    Hovels, Anke M.
    VALUE IN HEALTH, 2021, 24 (01) : 121 - 128
  • [46] Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer
    Rini, Brian I.
    CURRENT ONCOLOGY REPORTS, 2009, 11 (03) : 163 - 164
  • [47] Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer
    Sausan Abouharb
    Paul G. Corn
    Current Oncology Reports, 2013, 15 : 217 - 223
  • [48] The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
    Tsao, Che-Kai
    Cutting, Elena
    Martin, Jacob
    Oh, William K.
    THERAPEUTIC ADVANCES IN UROLOGY, 2014, 6 (03) : 97 - 104
  • [49] Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer
    Abouharb, Sausan
    Corn, Paul G.
    CURRENT ONCOLOGY REPORTS, 2013, 15 (03) : 217 - 223
  • [50] The role of abiraterone in the management of metastatic castration-resistant prostate cancer
    Rawlinson, Alex
    Mohammed, Aza
    Beatty, John
    Bell, Richard
    Miller, Marek
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (04) : 429 - 437